(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2009 (11.09.2009)

PCT

(10) International Publication Number
WO 2009/109844 A1

(51) **International Patent Classification**:
A61K 31/496 (2006.01) *A61P 25/18* (2006.01)

(21) **International Application Number**:
PCT/IB2009/000442

(22) **International Filing Date**:
4 March 2009 (04.03.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/034,947 7 March 2008 (07.03.2008) US

(71) **Applicant** *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **CURATOLO, William, John** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **HERBIG, Scott, Max** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **THOMBRE, Avinash, Govind** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **SHAH, Jaymin, Chandrakant** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **SHAMBLIN, Sheri, L.** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **LUKAS, Timothy** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **BRETT, William, Caldwell** [US/US]; 295 SW Summer Lake Drive, Bend, OR 97702 (US). **FRIESEN, Dwayne, Thomas** [US/US]; 60779 Currant Way, Bend, OR 97702 (US). **LYON, David, Keith** [US/US]; 20448 Klahani Drive, Bend, OR 97702 (US). **CRAIG, Christopher, Donovan** [US/US]; 1585 NW Fresno Avenue, Bend, OR 97701 (US).

(74) **Agents**: **RICHARDSON, Peter, C.** et al.; Pfizer Inc., 150 East 42nd Street, New York, NY 10017 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2009/109844 A1

(54) **Title**: METHODS, DOSAGE FORMS, AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD

(57) **Abstract**: The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve ($AUC_{0\text{-}inf}$) of the ziprasidone in the human subsequent to said administering is from 70% to 140% of the mean area under the ziprasidone serum concentration versus time curve ($AUC_{0\text{-}inf}$) resulting from administration of a control ziprasidone immediate release oral capsule containing the same amount of ziprasidone to a cohort of humans in a fed state.